Source: Therma Bright.
  • Therma Bright (THRM) has announced a C$6M private placement with institutional investors
  • The company will use the proceeds for general working capital purposes
  • It expects the placement to close on or about February 18, 2022
  • Therma Bright is a medical diagnostic and device technology company
  • Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share

Therma Bright (THRM) has announced a C$6M private placement with institutional investors.

The company will issue 20M units priced at $0.30 comprised of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share for $0.375 for five years following the issuance date.

The company will use the proceeds for general working capital purposes.

It expects the placement to close on or about February 18, 2022.

H.C. Wainwright & Co. is acting as the exclusive placement agent.

Therma Bright is a medical diagnostic and device technology company. It developed the AcuVid COVID-19 Rapid Antigen Saliva Test.

Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share as of 12:43 pm EST.

More From The Market Online
Traveling data

POET increases production capacity to meet AI demand

POET Technologies will expand production capacity for its optical engines in Malaysia to better capitalize on demand for AI infrastructure.
BlaxkBerry logo

BlackBerry AtHoc moves toward FedRAMP high authorization

BlackBerry's (TSX:BB) AtHoc critical event management solution, BlackBerry is listed as in process for federal high authorization.
An artificial intelligence robot and a rising stock chart

Poet Technologies to delist from the TSXV

Poet Technologies (TSXV:PTK) reveals it will delist its shares from the TSXV, but will continue to list its shares on the NASDAQ.